Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms

The European Journal of Neuroscience
Mauro GiorgiGiuseppe Sancesario

Abstract

Dysregulation of dopamine receptors is thought to underlie levodopa-induced dyskinesias in experimental models of Parkinson's disease. It is unknown whether an imbalance of the second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is involved in the alterations of levodopa/dopamine signal transduction. We examined cAMP and cGMP signalling in the interconnected cortico-striatal-pallidal loop at the peak of levodopa-induced dyskinesias in rats with 6-hydroxydopamine lesions in the substantia nigra. In addition, we examined the role of phosphodiesterase (PDE) and the rate of cAMP and cGMP degradation on the severity of levodopa-induced dyskinesias in animals pretreated with PDE inhibitor, zaprinast. Unilateral lesion of substantia nigra led to an increase in cAMP but a decrease in cGMP levels in the ipsilateral basal ganglia. After chronic levodopa treatment, cAMP and cGMP were differentially regulated in eukinetic animals: the cAMP level increased in the cortex and striatum but decreased in the globus pallidus of both hemispheres, whereas the cGMP decreased below baseline levels in the contralateral cortico-striatal-pallidal regions. In dyskinetic animals chronic levodopa treatment le...Continue Reading

References

Feb 22, 1992·The Journal of Comparative Neurology·K SongF A Mendelsohn
Oct 1, 1991·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D KoeslingG Schultz
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·W S YoungM R Brann
Jan 1, 1980·Annals of the New York Academy of Sciences·J H WangP B Chock
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·D G ColeS E Hyman
Aug 1, 1997·Trends in Biochemical Sciences·S M LohmannH R De Jonge
Jun 23, 1998·The Journal of Biological Chemistry·S H SoderlingJ A Beavo
Oct 15, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Feb 22, 2001·Annual Review of Physiology·B Wedel, D Garbers
Aug 3, 2001·Nature Reviews. Neuroscience·E BezardC E Gross
Jun 28, 2002·Physiological Reviews·U Benjamin Kaupp, Reinhard Seifert
Oct 3, 2002·Journal of Neurochemistry·Victoria WykesJohn Garthwaite
Sep 25, 2003·Biochemical Society Transactions·D M F Cooper
Oct 14, 2003·Experimental Neurology·Brian HenryJonathan M Brotchie
Jun 11, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Barbara PicconiMonica Di Luca
Jun 16, 2004·Parkinsonism & Related Disorders·Kerstin HåkanssonGilberto Fisone
Aug 11, 2004·Behavioural Brain Research·Mauro GiorgiAntonella Gasbarri
Aug 13, 2004·The European Journal of Neuroscience·Giuseppe SancesarioGiorgio Bernardi
Oct 12, 2004·Neurobiology of Disease·Christine KonradiM Angela Cenci
Oct 30, 2004·Annals of Neurology·Incarnation AubertErwan Bezard
Dec 21, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·S ThomasI Gottlob
Apr 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine Widnell
Dec 6, 2005·Brain Research Bulletin·Peter Hagell, M Angela Cenci
Mar 17, 2006·Journal of Neurochemistry·Manolo CartaM A Cenci
Aug 26, 2006·Nature Clinical Practice. Neurology·C Warren OlanowFabrizio Stocchi

❮ Previous
Next ❯

Citations

Dec 25, 2010·Brain : a Journal of Neurology·Barbara PicconiPaolo Calabresi
Jun 6, 2012·Parkinson's Disease·Veronica GhiglieriPaolo Calabresi
Nov 22, 2014·Proceedings of the National Academy of Sciences of the United States of America·Yotam SagiPaul Greengard
Oct 18, 2011·Journal of Neuroscience Methods·Patrick Oeckl, Boris Ferger
Aug 9, 2011·Journal of Chemical Neuroanatomy·Lars Schack KruseChristina Kruuse
Jan 30, 2010·Parkinsonism & Related Disorders·Céline Guigoni, Erwan Bezard
Mar 18, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sabeena SharmaRahul Deshmukh
Aug 29, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Paolo CalabresiTed M Dawson
Jul 27, 2015·Brain : a Journal of Neurology·Flavia NiccoliniMarios Politis
Jul 26, 2015·Progress in Neurobiology·Matthieu F BastideErwan Bézard
Feb 16, 2015·Cellular and Molecular Life Sciences : CMLS·Flavia NiccoliniMarios Politis
Apr 19, 2015·Molecular Neurodegeneration·Sandeep Vasant More, Dong-Kug Choi
Oct 5, 2014·Behavioural Brain Research·Mauro GiorgiAntonella Gasbarri
Apr 3, 2016·The International Journal of Neuropsychopharmacology·Pim R A HeckmanJos Prickaerts
Mar 7, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Goichi BeckStella M Papa
Jul 20, 2018·The European Journal of Neuroscience·Keila Bariotto-Dos-SantosElaine Del Bel
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie
Jun 4, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Gennaro PaganoMarios Politis
Dec 25, 2019·Expert Opinion on Therapeutic Patents·Agnieszka Zagórska
Feb 12, 2020·International Journal of Molecular Sciences·Vincenza D'AngeloGiuseppe Sancesario
Oct 5, 2017·Current Neurology and Neuroscience Reports·Gennaro PaganoMarios Politis
Jul 1, 2016·Reviews in the Neurosciences·Joseph R PhillipsAhmed A Moustafa
Jan 15, 2019·Movement Disorders Clinical Practice·Antonio P StrafellaUNKNOWN IPMDS‐Neuroimaging Study Group
Jul 17, 2020·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Do-Yeon KimHee-Sun Kim
Sep 28, 2018·Molecular Neurobiology·José-Rubén García-MontesRosario Moratalla
Apr 3, 2019·Journal of Neural Transmission·Shenyu ZhaiD James Surmeier
Aug 28, 2020·The European Journal of Neuroscience·Alessandro StefaniSalvatore Galati
Mar 29, 2021·Pharmacology, Biochemistry, and Behavior·Takeshi EnomotoKazuhito Ikeda
Apr 4, 2021·International Journal of Molecular Sciences·Vincenza D'AngeloGiuseppe Sancesario
Jul 16, 2013·European Journal of Pharmacology·Sorabh SharmaPyare Lal Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.